BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCode’s lead therapeutic candidate, TTX-MC138, in a feline patient with spontaneous metastatic breast cancer.
In the study, a feline patient that had failed prior standard-of-care treatment with multiple rounds of chemotherapy for advanced metastatic mammary carcinoma and was at the end of its life expectancy, was dosed with TTX-MC138. Delivery of TTX-MC138 to the metastatic lesions was demonstrated using noninvasive magnetic resonance imaging (MRI), which was confirmed by fluorescence microscopy of biopsy samples. Together, these two methods of measurement provide strong evidence that TTX-MC138, as designed, is delivered to metastatic tumor cells after intravenous injection. Dosing with TTX-MC138 resulted in target engagement and durable inhibition of the microRNA-10b target and induction of the downstream metastasis suppressor, HOXD10, lasting as long as three months after injection. The patient tolerated the injection well with no adverse effects; vital signs remained within the normal range and subsequently the animal resumed normal eating, drinking, and grooming. Seven weeks after the first dose, the feline patient was dosed a second time and tolerated the injection well. The patient survived for five (5) additional months compared to the animal’s life expectancy prior to dosing.
Frontiers in Oncology is the third most-cited journal in its field with more than 155,000 citations and 60 million views across 17,000 articles. The case study was led by Dr. Anna Moore, Professor and Director of the Precision Health Program at Michigan State University and scientific co-founder of TransCode.
Feline mammary carcinoma (FMC), the third most common cancer in cats and highly metastatic, has high resemblance to human breast cancer in terms of relative age at onset, incidence, risk factors, prognostic aspects, histopathology, biological behavior, metastatic pattern and response to therapy.
“TTX-MC138 has already been shown to induce durable regression of metastatic disease in murine models, so with an outlook toward clinical translation, our next step was to test the applicability of our therapeutic strategy in larger animals,” commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. “As with prior studies, we believe the data from this feline case study support advancement of TTX-MC138 into the clinic. These preclinical data increase our confidence that TTX-MC138 has the potential to become a novel first-in-class therapeutic approach against metastatic breast cancer that could ultimately improve clinical outcomes in human patients.”
“Demonstrating the delivery of our first-in-class RNA targeted therapeutic in animal models is an important step in the preclinical development process and further de-risks our approach,” added Michael Dudley, co-founder, president and CEO of TransCode. “As we have previously indicated, we’re on track to submit an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 first-in-human (FIH) clinical trial with TTX-MC138 in cancer patients with advanced solid tumors.”
TTX-MC138 targets microRNA-10b, believed to drive metastatic disease. TTX-MC138 has been validated preclinically in multiple indications and has previously been shown to induce durable regression of metastatic disease in murine models of disseminated breast cancer.
About TransCode Therapeutics
TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively. TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I, or RIG-I, designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the preclinical results or expected clinical results of TransCode’s therapeutic candidates, statements concerning the results of RNA research, statements concerning the potential for treating cancer with RNA therapeutics, statements concerning the timing and outcome of expected regulatory filings and clinical trials, including the filing of an eIND for the planned first-in-human study of TTX-MC138, statements concerning the timing and outcome of this study, including whether this study will demonstrate proof-of-mechanism, and statements concerning TransCode’s development programs and TTX technology platform generally. Of note, a Phase 0 clinical trial is an exploratory study, conducted under an exploratory Investigational New Drug (eIND) application. Exploratory IND studies usually involve very limited human exposure to evaluate mechanism of action in order to inform potential clinical evaluation in future clinical studies, but otherwise have no therapeutic intent. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.
For more information, please contact:
TransCode Therapeutics, Inc.
Alan Freidman, VP Investor Relations
alan.freidman@transcodetherapeutics.com
Dave Gentry, CEO
RedChip Companies
Office: 1.800.RED.CHIP (733.2447)
Cell: 407.491.4498
RNAZ@redchip.com
